M&A Deal Summary |
|
|---|---|
| Date | 2015-12-30 |
| Target | Galena Biopharma - Zuplenz |
| Sector | Medical Products |
| Buyer(s) | Midatech Pharma |
| Sellers(s) | Galena Biopharma |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 18 |
| Revenue | 8M GBP (2017) |
Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Midatech Pharma was founded in 2000 and is based in Cardiff, the United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2015 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-02 |
DARA BioSciences
Raleigh, North Carolina, United States DARA BioSciences, Inc. is a clinical stage pharmaceutical development company that acquires high quality, promising therapeutic molecules in early stage development (late pre-clinical or Phase 1). |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-11-12 |
Fortovia Therapeutics
Raleigh, North Carolina, United States Fortovia Therapeutics is a pharmaceutical company focused on oncology supportive care, with five marketed products in their portfolio. These products help patients manage the impact of their cancer as well as the side effects of their cancer therapies. Fortovia Therapeutics was founded in 2002 and is based in Raleigh, North Carolina. |
Sell | $19M |
| Category | Company |
|---|---|
| Founded | 2003 |
| Sector | Life Science |
| Employees | 22 |
| Revenue | 9M USD (2014) |
Galena Biopharma, Inc. is a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-07-01 |
Galena Biopharma - Zuplenz
United States Galena Biopharma - Zuplenz® (ondansetron) Oral Soluble Film, is approved by the U.S. Food and Drug Administration for use in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) |
Buy | - |
